Noelle Frey, MD
Enriched profileDirector, Clinical Cellular Therapy, Center for Cell Therapy and Transplant · University of Pennsylvania
Noelle Frey is Director, Clinical Cellular Therapy, Center for Cell Therapy and Transplant at University of Pennsylvania. OpenAlex indexes 461 publications with 24,307 citations (h-index 54); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 10% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 23 Oct 2026
Overview
Updated 24 Oct 2026
Noelle Frey, MD, is Director, Clinical Cellular Therapy, Center for Cell Therapy and Transplant at University of Pennsylvania. The public record shows 461 publications with 24,307 citations (h-index 54), centered on CAR-T cell therapy research, T-cell and B-cell Immunology, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 12 companies.
- Most recent indexed publication: 2026 · Blood
- Top research focus: CAR-T cell therapy research
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 24 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 17 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 128.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 24 Oct 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- CD45BE-HSPC + CART-45 Cells
Sponsor: University of Pennsylvania
- CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
Sponsor: University of Pennsylvania
Industry payments
Updated 24 Oct 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Kite Pharma, Inc.Program year20258 payments$14,120openpaymentsdata.cms.gov ↗
- Autolus IncProgram year20252 payments
- Celgene CorporationProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
68.5%Kinase inhibitor50.7%Iclusig65%Tasigna35%Part D<11 patientsIsocitrate Dehydrogenase 2 Inhibitor17.8%Idhifa100%Part D<11 patientsDermatology
16.4%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor16.4%Acyclovir100%Part D<11 patientsMetabolism & gastrointestinal
15.1%Proton pump inhibitor15.1%Pantoprazole Sodium100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 24 Oct 2026
60 congress contributions (2011–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Cytotoxic, natural killer-like ex-tissue resident memory T-cells circulate in human chronic graft-versus-host disease at diagnosis
ASH Annual Meeting
ASH2025Co-author - IL18-armored CAR T cells in relapsed/refractory B cell acute lymphoblastic leukemia
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 24 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Most-cited works
by citation count (OpenAlex)- 01Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaArticle5,409 citations2014
- 02
- 03
- 04
- 05
Network
Updated 24 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 24 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/noelle-frey-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 24 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗
- MD
Columbia University (medical school)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗
Editorial & leadership roles
journal and society appointments- Affiliation: ASTCT (American Society for Transplantation and Cellular Therapy)
listed on Penn Medicine profile
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →pennmedicine.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.upenn.edu ↗
Media & interviews
press, podcasts and appearances- Video interview: "Dr. Frey on CAR T-Cell Therapy in High-Risk ALL" (CGTLive; also on OncLive)
2019 per search summary
2019provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cgtlive.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vjhemonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Carl June, MD
University of Pennsylvania
Raquel Gur, MD
University of Pennsylvania
Howard Herrmann, MD
University of Pennsylvania
Robert Vonderheide, MD
University of Pennsylvania
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center